Skip to content

Randomized Controlled Prospective Study on the Treatment of Hyperuricemia with Niaosuanning (Jianpi Yishen Huazhuo) Granules

Randomized Controlled Prospective Study on the Treatment of Hyperuricemia with Niaosuanning Granules

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400079853
Enrollment
Unknown
Registered
2024-01-15
Start date
2024-01-20
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

Traditional Chinese medicine granule group: Niaosuanning (Jianpi Yishen Huazhuo) Granules, 1 dose each time, 100-150ml boiled water, twice a day, orally after meals for 28 days.
Traditional Chinese medicine decoction group:Niaosuanning (Jianpi Yishen Huazhuo) traditional Chinese medicine decoction, 1 dose each time, 250ml each time, twice a day, orally after meals for 28 days
Western medicine group:The dosage of 40mg was 1 tablet once a day, taken orally after meals for 28 days.

Sponsors

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meets the diagnostic criteria for Western and Traditional Chinese Medicine syndromes; (2) Meet the starting point for starting uric acid lowering medication treatment; (3) Individuals aged = 18 and = 80 years old; (4) Patient signs informed consent form

Exclusion criteria

Exclusion criteria: (1) the level of aspartate aminotransferase or alanine aminotransferase is 2 times or more than the upper limit of the normal value; (2) has a long history of glucocorticoid use; (3) patients whose creatinine clearance rate is lower than 30ml/min; (4) pregnant and lactating women; (5) patients with a history of alcoholism; (6) history of other diseases, and the use of drugs affects the efficacy of this study. (7) history of chronic severe infection, any current infection and any malignant tumor; (8) patients with severe primary diseases and psychosis such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system; (9) patients who are allergic to experimental drugs; (10) patients who participated in other clinical trials within 4 weeks before screening.

Design outcomes

Primary

MeasureTime frame
Serum uric acid;

Secondary

MeasureTime frame
Ururic acid;

Countries

China

Contacts

Public ContactGuangxing Chen

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Baiyun Hospital

cgx02@hotmail.com+86 137 1160 2757

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026